Non-small Cell Lung Cancer
Conditions
Keywords
Simotinib, Non-small Cell Lung Cancer
Brief summary
The primary objective is to assess the safety and tolerability of multiple doses of Simotinib Hydrochloride in NSCLC patients. The secondary objective is to determine the pharmacokinetic (PK) profile and explore the preliminary anti-tumor activity.
Interventions
Sponsors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with histologically or cytologically confirmed diagnosis of advanced NSCLC, who were previously treated with at least one platinum-based chemotherapy regimen, but had disease relapse; * Patients have ended their chemotherapy or radiotherapy at least 4 weeks prior to study entry and have recovered from any previous toxicity; * EGFR mutation positive (such as E19del、L858R、L861Q、G719X, etc.); * Patients with at least one measurable lesion meeting RECIST; * ECOG performance status 0-2; * Life expectancy ≥12 weeks; * Adequate bone marrow function: ANC ≥1.5 × 109/L, PLT≥80 ×109/L, HB ≥90 g/L; * Adequate hepatic function: serum bilirubin ≤ 2 × ULN, AST and ALT ≤ 2.5 × ULN, and ≤ 5 × ULN are acceptable if the liver has tumor involvement; * Adequate renal function: endogenous creatinine clearance rate (CrCl) ≥ 60 mL/min or serum creatinine ≤ 1.5 × ULN; * Females with childbearing potential must have a negative pregnancy test within 7 days prior to treatment and use an approved contraceptive method during the study; * Males must be surgically sterile or use an approved contraceptive method during the study.
Exclusion criteria
* Patients who were previously treated by EGFR inhibitor or other molecular targeting drugs (micromolecular drugs or monoclonal antibodies) such as Iressa, Tarceva, Sutent, Nexavar, Sprycel, Erbitux, Nimotuzumab, Icotinib, Herceptin, etc.; * The known hypersensitivity to Simotinib or any of the excipients; * Concurrent treatment with rifampin, rifabutin, rifapentine, dexamethasone, phenytoin sodium, carbamazepine, phenobarbital, Hypericum perforatum, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin; * CNS metastasis diagnosed recently which has not received surgery or radiotherapy; * Evidence of interstitial lung disease; * Pre-existing idiopathic pulmonary fibrosis as evidenced by CT scan at baseline; * Any serious or uncontrollable systemic disease (such as unstable respiratory disorders, cardiovascular, hepatic or kidney disorders); * Any unstable systemic disorders (including active infection, uncontrollable hypertension, unstable angina pectoris, congestive heart failure, liver and kidney disorders or metabolism disease); * Other malignancies diagnosed within the last 5 years with the exception of completely cured cervical cancer in situ, or basal and squamous cell skin cancer; * Any remarkable eye disorders, especially severe dry eye syndrome, keratoconjunctivitis sicca, herpes keratitis; * History of nerve or psychiatric disorders, including epilepsy or dementia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose (MTD) | 28 days |
Secondary
| Measure | Time frame |
|---|---|
| The maximum plasma concentration (Cmax) | d1,d8,d9,d10,d15 |
| The time to Cmax (tmax) | d1,d8,d9,d10,d15 |
| Area under the plasma concentration-time curve (AUC) | d1,d8,d9,d10,d15 |
| Overall Response Rate (ORR) | 1 year |
| Progression-free Survival (PFS) | 1 year |
Countries
China
Contacts
Primary ContactYuankai Shi, MD
Outcome results
None listed